Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1990 1
1991 1
1992 1
1993 6
1994 9
1995 4
1996 1
1997 1
1998 2
1999 6
2000 1
2001 9
2002 7
2003 11
2004 6
2005 6
2006 5
2007 6
2008 12
2009 9
2010 12
2011 17
2012 14
2013 14
2014 17
2015 11
2016 10
2017 13
2018 12
2019 12
2020 18
2021 11
2022 7
2023 3
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Unresectable Adult Hepatocellular Carcinoma"
Page 1
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Chiang CL, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15. Lancet Gastroenterol Hepatol. 2023. PMID: 36529152 Clinical Trial.
BACKGROUND: The synergy between locoregional therapies and immune checkpoint inhibitors has not been investigated as conversion therapy for unresectable hepatocellular carcinoma. We aimed to investigate the activity of sequential transarterial chemoembolisati …
BACKGROUND: The synergy between locoregional therapies and immune checkpoint inhibitors has not been investigated as conversion therapy for …
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Salem R, et al. Hepatology. 2021 Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11. Hepatology. 2021. PMID: 33739462 Free PMC article.
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. The aim of the LEGACY (Local radioEmbolization using Glass Microspheres for the Assessment of Tumor Control with Y-90) s …
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresecta …
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Hong TS, et al. J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14. J Clin Oncol. 2016. PMID: 26668346 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). ...Sample size was calculated to demonstrate > 80% local control (LC) defined by R …
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma ( …
External beam radiotherapy for unresectable hepatocellular carcinoma.
Abdel-Rahman O, Elsayed Z. Abdel-Rahman O, et al. Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2. Cochrane Database Syst Rev. 2017. PMID: 28267205 Free PMC article. Review.
While surgical resection and liver transplantation are the main curative treatments, only around 20% of people with early hepatocellular carcinoma may benefit from these therapies. Current treatment options for unresectable hepatocellular carcinoma …
While surgical resection and liver transplantation are the main curative treatments, only around 20% of people with early hepatocellular …
Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.
Chia-Hsien Cheng J, Chuang VP, Cheng SH, Lin YM, Cheng TI, Yang PS, Jian JJ, You DL, Horng CF, Huang AT. Chia-Hsien Cheng J, et al. Int J Cancer. 2001 Aug 20;96(4):243-52. doi: 10.1002/ijc.1022. Int J Cancer. 2001. PMID: 11474499
The purpose of our study was to evaluate the outcome, patterns of failure, and toxicity for patients with unresectable hepatocellular carcinoma (HCC) treated with radiotherapy, transcatheter arterial chemoembolization (TACE), or combined TACE and radiotherapy …
The purpose of our study was to evaluate the outcome, patterns of failure, and toxicity for patients with unresectable hepatocellu …
Stereotactic body radiation therapy for hepatocellular carcinoma.
Lo SS, Dawson LA, Kim EY, Mayr NA, Wang JZ, Huang Z, Cardenes HR. Lo SS, et al. Discov Med. 2010 May;9(48):404-10. Discov Med. 2010. PMID: 20515608 Free article. Review.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in adults and it is frequently associated with cirrhosis. ...There are a limited number of clinical trials examining the use of SBRT in patients with HCC and very good local …
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in adults and it is frequently associated with c …
Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.
Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Sanford NN, et al. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):64-72. doi: 10.1016/j.ijrobp.2019.01.076. Epub 2019 Jan 23. Int J Radiat Oncol Biol Phys. 2019. PMID: 30684667
PURPOSE: Ablative radiation therapy is increasingly being used for hepatocellular carcinoma (HCC) resulting in excellent local control rates; however, patients without evidence of disease progression often die from liver failure. ...We therefore sought to com …
PURPOSE: Ablative radiation therapy is increasingly being used for hepatocellular carcinoma (HCC) resulting in excellent lo …
Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma.
Song Z, Ye J, Wang Y, Li Y, Wang W. Song Z, et al. J Cancer Res Ther. 2019;15(7):1553-1560. doi: 10.4103/jcrt.JCRT_629_19. J Cancer Res Ther. 2019. PMID: 31939437 Free article.
PURPOSE: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between February 2013 and March 2019, 57 patients with 108 unresectable HCC …
PURPOSE: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatoce …
Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM. Ji R, et al. Medicine (Baltimore). 2022 Jan 28;101(4):e28545. doi: 10.1097/MD.0000000000028545. Medicine (Baltimore). 2022. PMID: 35089192 Free PMC article.
Stereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for unresectable hepatocellular carcinoma (HCC). Whether its efficacy is comparable to radiofrequency ablation (RFA), a recommended therapy for unresectable HCC, is unknown. The pre …
Stereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for unresectable hepatocellular carcinoma (HCC). …
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R, Siegel E, Makhoul I, Williamson S. Govindarajan R, et al. Am J Clin Oncol. 2013 Jun;36(3):254-7. doi: 10.1097/COC.0b013e318248d83f. Am J Clin Oncol. 2013. PMID: 22643560 Clinical Trial.
PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not candidates for local therapy. ...CONCLUSIONS: The 28% progression-free survival rate at 27 weeks was not significantly higher than th …
PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not …
243 results